ArticleNature communications2026
Highly efficient expression of DNA-peptide conjugates in growth-arrested cells.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Efficient nuclear delivery of DNA remains a major challenge in non-viral gene therapy. While nuclear localization signal (NLS) peptides have been explored for enhancing nuclear translocation of DNA, their efficacy has been limited by DNA-peptide conjugation strategies. Leveraging E. coli tRNA guanine transglycosylase, we present a modular workflow for generating DNA oligonucleotide-peptide conjugates which are ligated to linear DNA to generate peptide-modified gene cassettes (DNA-PepTAG). Using an eGFP reporter delivered via lipofection to growth-arrested cells, NLS-modified gene cassettes significantly increases nuclear localization, mRNA transcription, and expression up to ~10 fold compared to unmodified gene cassettes. Screening multiple NLS peptides in growth-arrested human cell lines reveal cell-type-specific preferences for nuclear translocation of DNA cargo. Two NLS peptides, PLSCR-1 and extSV40, exhibit consistently high expression across tested cell types, indicating broad applicability for nuclear delivery. We evaluate the generality of our approach by delivering DNA payloads encoding for both cytosolic and secreted proteins, as well as gene cassettes ranging in size from 1.3 kbp to 7 kbp. These findings support the potential of DNA-NLS conjugates as a viable strategy for non-viral gene therapy, enabling enhanced nuclear delivery of therapeutic genes while minimizing the required DNA dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.